[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA95304C2 - Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов - Google Patents

Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов

Info

Publication number
UA95304C2
UA95304C2 UAA200902033A UAA200902033A UA95304C2 UA 95304 C2 UA95304 C2 UA 95304C2 UA A200902033 A UAA200902033 A UA A200902033A UA A200902033 A UAA200902033 A UA A200902033A UA 95304 C2 UA95304 C2 UA 95304C2
Authority
UA
Ukraine
Prior art keywords
vascular disorders
prevention
dii4
dll4 antagonists
antibody
Prior art date
Application number
UAA200902033A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стенли Дж. Уиганд
Николас Дж. ПАПАДОПУЛОС
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of UA95304C2 publication Critical patent/UA95304C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается способа лечения ишемических или васкулярных заболеваний путем введения вещества, способного ингибировать активность Δ -подобного лиганда 4 (Dll4 человека) нуждающегося в этом субъекта. Вещество представляет собой антитело против Dll4 или фрагмент антитела, способные ингибировать связывание Dll4 с рецептором Notch.
UAA200902033A 2006-08-07 2007-08-07 Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов UA95304C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83600306P 2006-08-07 2006-08-07

Publications (1)

Publication Number Publication Date
UA95304C2 true UA95304C2 (ru) 2011-07-25

Family

ID=38904599

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200902033A UA95304C2 (ru) 2006-08-07 2007-08-07 Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов

Country Status (33)

Country Link
US (1) US20080181893A1 (ru)
EP (1) EP2054082B1 (ru)
JP (1) JP5529536B2 (ru)
KR (1) KR101497355B1 (ru)
CN (1) CN101500605B (ru)
AU (1) AU2007281916B2 (ru)
BR (1) BRPI0716424B8 (ru)
CA (1) CA2660235C (ru)
CO (1) CO6150190A2 (ru)
CR (1) CR10627A (ru)
DK (1) DK2054082T3 (ru)
ES (1) ES2398253T3 (ru)
GT (1) GT200900029A (ru)
HK (1) HK1137339A1 (ru)
HR (1) HRP20130271T1 (ru)
IL (1) IL196612A (ru)
MA (1) MA30667B1 (ru)
ME (1) ME00591A (ru)
MX (1) MX2009000674A (ru)
MY (1) MY150092A (ru)
NO (1) NO341857B1 (ru)
NZ (1) NZ574794A (ru)
PL (1) PL2054082T3 (ru)
PT (1) PT2054082E (ru)
RS (1) RS52685B (ru)
RU (1) RU2429876C2 (ru)
SG (1) SG174033A1 (ru)
SI (1) SI2054082T1 (ru)
SV (1) SV2009003161A (ru)
TN (1) TN2009000036A1 (ru)
UA (1) UA95304C2 (ru)
WO (1) WO2008019144A2 (ru)
ZA (1) ZA200900337B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
JP5859307B2 (ja) * 2008-09-10 2016-02-10 ジェネンテック， インコーポレイテッド 眼の血管新生を阻害する方法
JP5778577B2 (ja) * 2008-09-19 2015-09-16 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2011008641A1 (en) 2009-07-13 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methids of modulating angiogenesis and treatment of angiogenesis-related diseases
SG178930A1 (en) 2009-08-29 2012-04-27 Abbott Lab Therapeutic dll4 binding proteins
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
AU2011223919B2 (en) * 2010-03-02 2015-03-19 Abbvie Inc. Therapeutic DLL4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11679126B2 (en) 2016-11-17 2023-06-20 Chldren's Medical Center Corporation Methods to enhance microvascular engraftment of bioengineered and primary tissues
WO2023063842A1 (ru) 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
AU2006287228B2 (en) * 2005-09-01 2012-12-13 Alora Biopharma, Inc. Methods for using and identifying modulators of Delta-like 4
CL2007001624A1 (es) * 2006-06-06 2008-01-18 Genentech Inc Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.

Also Published As

Publication number Publication date
AU2007281916B2 (en) 2012-06-28
BRPI0716424A2 (pt) 2014-05-20
SG174033A1 (en) 2011-09-29
GT200900029A (es) 2009-11-17
EP2054082A2 (en) 2009-05-06
BRPI0716424B8 (pt) 2021-05-25
IL196612A0 (en) 2011-08-01
CN101500605A (zh) 2009-08-05
RS52685B (en) 2013-08-30
MX2009000674A (es) 2009-02-04
CR10627A (es) 2009-04-14
CA2660235C (en) 2015-09-22
NO20090984L (no) 2009-03-04
ZA200900337B (en) 2009-12-30
IL196612A (en) 2012-02-29
RU2429876C2 (ru) 2011-09-27
HK1137339A1 (en) 2010-07-30
US20080181893A1 (en) 2008-07-31
KR101497355B1 (ko) 2015-03-02
KR20090039823A (ko) 2009-04-22
NO341857B1 (no) 2018-02-12
MY150092A (en) 2013-11-29
ME00591B (me) 2011-12-20
NZ574794A (en) 2011-06-30
JP5529536B2 (ja) 2014-06-25
WO2008019144A3 (en) 2008-03-27
SV2009003161A (es) 2010-02-01
JP2010500355A (ja) 2010-01-07
PL2054082T3 (pl) 2013-05-31
BRPI0716424B1 (pt) 2018-06-26
CN101500605B (zh) 2014-04-30
CA2660235A1 (en) 2008-02-14
DK2054082T3 (da) 2013-01-21
TN2009000036A1 (en) 2010-08-19
ME00591A (en) 2011-12-20
HRP20130271T1 (hr) 2013-04-30
AU2007281916A1 (en) 2008-02-14
ES2398253T3 (es) 2013-03-14
MA30667B1 (fr) 2009-08-03
SI2054082T1 (sl) 2013-04-30
RU2009107921A (ru) 2010-09-20
CO6150190A2 (es) 2010-04-20
EP2054082B1 (en) 2012-12-26
WO2008019144A2 (en) 2008-02-14
PT2054082E (pt) 2013-03-07

Similar Documents

Publication Publication Date Title
UA95304C2 (ru) Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
WO2005107726A3 (en) Method for the treatment of back pain
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
RS54156B1 (en) COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
MX2009013656A (es) Composiciones terapeuticas anti-cd20 y metodos.
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
NZ567441A (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases.
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
UA94899C2 (ru) Фиксированное дозирование антител к her
IL178121A0 (en) Therapeutic use of anti-cs1 antibodies
WO2007058990A3 (en) Therapy using cytokine inhibitors
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2011088215A3 (en) Notch1 binding agents and methods of use thereof
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
GB2451987A (en) Assessment of the effects of topical administration of chemodenervating pharmaceuticals
DE602007006280D1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer